Scarica l'app Stockscreener
5.91
3.90%
-0.24
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$6.15
Aprire:
$6.14
Volume 24 ore:
1.27M
Relative Volume:
0.89
Capitalizzazione di mercato:
$433.40M
Reddito:
-
Utile/perdita netta:
$-56.17M
Rapporto P/E:
-3.2888
EPS:
-1.797
Flusso di cassa netto:
$-39.99M
1 W Prestazione:
+32.81%
1M Prestazione:
+58.87%
6M Prestazione:
+271.70%
1 anno Prestazione:
+2,074%
Intervallo 1D:
$5.82
$6.45
Intervallo di 1 settimana:
$5.80
$7.51
Portata 52W:
$0.243
$7.51
Relmada Therapeutics Inc Stock (RLMD) Company Profile
Nome
Relmada Therapeutics Inc
Settore
Industria
Telefono
646 876 3459
Indirizzo
2222 PONCE DE LEON BLVD. 3RD FLOOR, CORAL GABLES, NY
Compare RLMD vs GOODO, PSNYW, SHMD, DWLD, QQQE
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
| 3.03 | 0 | 0 | 0 | 0 | 0.00 | |
GOODO
Gladstone Commercial Corporation
|
19.87 | 372.90M | 0 | 0 | 0 | 0.00 |
|
PSNYW
Polestar Automotive Holding Uk
|
3.86 | 357.07M | 2.07B | -1.42B | -1.37B | -0.6765 |
|
SHMD
Schmid Group N V
|
6.31 | 350.85M | 0 | 0 | 0 | 0.00 |
|
DWLD
Davis Select Worldwide ETF
|
44.12 | 0 | 0 | 0 | 0 | 0.00 |
|
QQQE
Direxion NASDAQ-100 Equal Weigh
|
99.94 | 0 | 0 | 0 | 0 | 0.00 |
Relmada Therapeutics Inc Stock (RLMD) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-23 | Ripresa | Leerink Partners | Outperform |
| 2025-12-22 | Iniziato | Jefferies | Buy |
| 2025-11-19 | Aggiornamento | Mizuho | Neutral → Outperform |
| 2024-12-05 | Downgrade | Mizuho | Outperform → Neutral |
| 2024-09-17 | Aggiornamento | Jefferies | Hold → Buy |
| 2024-06-05 | Downgrade | Goldman | Neutral → Sell |
| 2022-10-14 | Downgrade | Goldman | Buy → Neutral |
| 2022-10-14 | Downgrade | Guggenheim | Buy → Neutral |
| 2022-10-14 | Downgrade | Truist | Buy → Hold |
| 2022-10-13 | Downgrade | Oppenheimer | Outperform → Perform |
| 2021-11-18 | Iniziato | Mizuho | Buy |
| 2021-05-20 | Ripresa | Goldman | Buy |
| 2020-10-28 | Downgrade | Goldman | Buy → Neutral |
| 2020-07-14 | Iniziato | Oppenheimer | Outperform |
| 2020-05-04 | Iniziato | SunTrust | Buy |
| 2020-04-21 | Iniziato | Goldman | Buy |
| 2020-01-27 | Iniziato | Jefferies | Buy |
| 2020-01-10 | Iniziato | SVB Leerink | Outperform |
| 2019-12-16 | Iniziato | Guggenheim | Buy |
Mostra tutto
Relmada Therapeutics Inc Borsa (RLMD) Ultime notizie
50% and 61% Gains in a Single Day: Why XENE and RLMD Soared Today - AOL.com
Mizuho reiterates Relmada stock rating on positive cancer trial data By Investing.com - Investing.com Australia
Mizuho reiterates Relmada stock rating on positive cancer trial data - Investing.com
Mizuho Reiterates Outperform Rating on Relmada Therapeutics Inc (RLMD): pullback 'a buying opprotunity' - StreetInsider
RLMD Stock Soars Pre-Market: Phase 2 Bladder Cancer Trial Data Impresses Investors - MSN
Why Relmada Therapeutics (RLMD) Is Up 38.8% After $160M Raise And Positive NDV-01 Phase 2 Data - Yahoo Finance
Relmada Therapeutics, Inc. announced that it has received $159.999996 million in funding from a group of investors - marketscreener.com
RLMD Stock Surges 42% in a Week: Here's What You Should Know - sharewise.com
RLMD Shares Jump 42% Over the Past Week: Key Information You Need - Bitget
Relmada reports 76% response rate for bladder cancer therapy - Investing.com Nigeria
Relmada Therapeutics to Report Fourth Quarter 2025 Financial Results on Thursday, March 19, 2026 - The Manila Times
Biotech Relmada schedules March 19 call on Q4 2025 results - Stock Titan
Relmada Therapeutics secures $160M in PIPE financing - Investing.com Nigeria
Relmada Therapeutics to Present at the Leerink Partners Global Healthcare Conference - 富途牛牛
Relmada Therapeutics (NASDAQ:RLMD) Shares Gap DownTime to Sell? - MarketBeat
Relmada Therapeutics at Leerink Global: Strategic Shift to Uro-Oncology By Investing.com - Investing.com Canada
A Look At Relmada Therapeutics (RLMD) Valuation After NDV-01 Phase 2 Update And US$160 Million Private Placement - Yahoo Finance
Relmada’s NDV-01 shows strong 12-month results in hard-to-treat bladder cancer - Indian Pharma Post
A Look At Relmada Therapeutics (RLMD) Valuation After NDV‑01 Phase 2 Bladder Cancer Data - Sahm
Relmada Therapeutics reports 12-month Phase 2 interim data for NDV-01 - TipRanks
Relmada reports 76% response rate for bladder cancer therapy By Investing.com - Investing.com Canada
Relmada Therapeutics secures $160M in PIPE financing By Investing.com - Investing.com Canada
Relmada Therapeutics (RLMD) Stock Jumps 31% on Breakthrough Bladder Cancer Data - MEXC
Relmada Therapeutics (NASDAQ:RLMD) Reaches New 12-Month HighShould You Buy? - MarketBeat
Relmada Therapeutics Announces 76% 12-Month Complete Response Rate in Phase 2 NDV-01 Trial for High-Risk Non-Muscle Invasive Bladder Cancer - Minichart
Biotech Stocks To Add to Your WatchlistMarch 9th - MarketBeat
Relmada Therapeutics shares jump 25% after promising bladder cancer trial results - MSN
Mizuho reiterates Relmada stock rating on bladder cancer trial data By Investing.com - Investing.com UK
Relmada Therapeutics Shares Surge 40.8% on Promising Trial Data - Intellectia AI
Relmada Therapeutics Gains Attention with Promising Bladder Cancer Asset - timothysykes.com
Relmada Therapeutics Announces Oversubscribed $160.0 Million Private Placement Financing - Investing News Network
Relmada Therapeutics Reports 12-Month Phase 2 Interim Data for NDV-01 in Non-Muscle Invasive Bladder Cancer - Investing News Network
Relmada Therapeutics (RLMD) Stock Surges as Bladder Cancer Trial Shows 76% Response Rate - MEXC
Relmada Therapeutics jumps on NDV-01 12-month Phase 2 data and $160M private placement - Quiver Quantitative
Relmada Therapeutics, Inc. announced that it expects to receive $159.999996 million in funding from a group of investors - marketscreener.com
Relmada Therapeutics, Xenon Pharmaceuticals, Dianthus Therapeutics And Other Big Stocks Moving Higher On Monday - Benzinga
Mizuho reiterates Relmada stock rating on bladder cancer trial data - Investing.com
Relmada Therapeutics (RLMD) Raises $160 Million as NDV-01 Bladder Cancer Data Set Up Phase 3 - Bez Kabli
Why Is RLMD Stock Surging Premarket? NDV-01 Trial Update and $160M PIPE Deal - Tokenist
Why Is Relmada Therapeutics Stock Soaring Monday? - Bitget
Relmada Therapeutics (RLMD) Stock Jumps 31% on Promising Bladder Cancer Data - parameter.io
Relmada Therapeutics (RLMD) Stock Jumps 31% on Promising Bladder Cancer Data and $160M Financing - MoneyCheck
Mizuho Reiterates Outperform Rating on Relmada Therapeutics Inc (RLMD) following "home run with the 12-month data" - StreetInsider
Relmada Therapeutics Raises $160 Million in Private Placement of Stock and Pre-Funded Warrants - TradingView
12 Health Care Stocks Moving In Monday's Pre-Market Session - Benzinga
Why Is Relmada Therapeutics Stock (RLMD) Up Today? - TipRanks
Relmada Therapeutics (RLMD) Secures $160M through PIPE Financing - GuruFocus
Relmada Therapeutics prices 29.47M shares at $4.75 in private placement - TipRanks
Relmada Therapeutics (RLMD) Reports Promising 12-Month Data for NDV-01 Trial - GuruFocus
Relmada Therapeutics Raises Capital, Highlights Promising NDV-01 Data - TipRanks
Relmada Therapeutics recently announced positive data for its investigational drug NDV-01 in high-risk non-muscle invasive bladder cancer. - Bitget
Relmada Therapeutics Inc Azioni (RLMD) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Relmada Therapeutics Inc Azioni (RLMD) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Shenouda Maged | Chief Financial Officer |
Dec 15 '25 |
Buy |
4.12 |
11,665 |
48,060 |
800,000 |
| Shenouda Maged | Chief Financial Officer |
Nov 05 '25 |
Buy |
2.20 |
500,000 |
1,100,000 |
788,335 |
| Ence Chuck | CAO and COO |
Nov 05 '25 |
Buy |
2.20 |
136,000 |
299,200 |
403,931 |
| TRAVERSA SERGIO | Chief Executive Officer |
Nov 05 '25 |
Buy |
2.20 |
272,500 |
599,500 |
1,272,500 |
| Kelly Paul Edward | Chief Operating Officer |
Nov 05 '25 |
Buy |
2.20 |
90,000 |
198,000 |
502,295 |
| TRAVERSA SERGIO | Chief Executive Officer |
Aug 27 '25 |
Buy |
0.67 |
129,455 |
86,735 |
944,024 |
| TRAVERSA SERGIO | Chief Executive Officer |
Aug 26 '25 |
Buy |
0.62 |
80,545 |
49,938 |
814,569 |
| TRAVERSA SERGIO | Chief Executive Officer |
Aug 28 '25 |
Buy |
0.74 |
55,976 |
41,422 |
1,000,000 |
| Kelly Paul Edward | Chief Operating Officer |
May 16 '25 |
Buy |
0.43 |
200,000 |
86,060 |
412,295 |
| Shenouda Maged | Chief Financial Officer |
May 19 '25 |
Buy |
0.49 |
90,000 |
43,686 |
228,335 |
0.48%
1.21%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):